Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate

 Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and Maintenance Regimens without Conditioning Chemotherapy

Initial Phase 1 Clinical Data in Relapsed / Refractory B-cell Lymphoma Show Favorable Safety Profile, Complete Responses, and Persistence of FT522 Live Cells

Selective Targeting and Reduction of CD19+ B Cells Observed with Each FT522 Dose in Study’s First Low-dose Cohort without Conditioning Chemotherapy, Supporting Novel ADR Technology

https://www.globenewswire.com/news-release/2024/11/18/2982736/24675/en/Fate-Therapeutics-Highlights-FT522-Off-the-shelf-ADR-armed-CAR-NK-Cell-Product-Candidate-at-2024-ACR-Convergence.html